An Open-label, Non-comparative, Single Dose-Escalation Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B
Latest Information Update: 15 Jun 2025
At a glance
- Drugs ANB 002 (Primary)
- Indications Haemophilia B
- Focus Adverse reactions; Therapeutic Use
- Acronyms SAFRAN
- Sponsors Biocad
Most Recent Events
- 03 Dec 2024 Planned number of patients changed from 12 to 28.
- 10 Nov 2023 New trial record